Endocrine Therapy in Breast Cancer: Recent Advances in the Drugs Used

Mccarthy J. The breast: embryology, anatomy, and physiology. Aesthetic surgery of the breast; 1990; 3–17.
Cabioğlu N. Memenin Anatomisi ve Fizyolojisi. In: Meme Hastalıkları Kitabı. Ankara: Güneş Tıp Kitabevleri; 2012. p. 3–16.
Özgültekin R. Meme kanserinde etiyoloji ve risk faktörleri. In: Meme hastalıkları. İstanbul: Nobel Tıp Kitapevleri; 2001. p. 233–246.
Karaca M. Meme Kanseri Epidemiyolojisi Risk Faktörleri ve Risk Skorlama Sistemleri. In: Meme Kanseri. Akademisyen Kitabevi; 2019. p. 1–22.
Chang J, Clark GM, Allred DC, et al. Survival of patients with metastatic breast carcinoma. Cancer. 2003;97(3):545–553. doi: 10.1002/cncr.11083
WHO. Breast cancer 2024. (16/02/2024 tarihinde https://www.who.int/news-room/fact-sheets/detail/breast-cancer adresinden ulaşılmıştır).
Jatoi I, Chen BE, Anderson WF, et al. Breast Cancer Mortality Trends in the United States According to Estrogen Receptor Status and Age at Diagnosis. Journal of Clinical Oncology; 2007;25(13):1683–1690.
Özbaş S, Boylu Ş, Soyder A. Meme Kanseri Epidemiyolojisi. In: Meme Hastalıkları Kitabı. Ankara: Güneş Tıp Kitabevleri; 2012. p. 149–50.
NCCN. Breast cancer 2022. (17/02/2024 tarihinde https://www.nccn.org/patients/guidelines/content/PDF/breastcancerscreening-patient.pdf adresinden ulaşılmıştır).
Ellington TD, Miller JW, Henley SJ, et al. Trends in Breast Cancer Incidence, by Race, Ethnicity, and Age Among Women Aged ≥20 Years — United States, 1999–2018. The Morbidity and Mortality Weekly Report. 2022;71(2): 43–47.
Colditz GA. Cumulative Risk of Breast Cancer to Age 70 Years According to Risk Factor Status: Data from the Nurses’ Health Study. American Journal of Epidemiology; 2000;152(10): 950–964.
Rosner B, Colditz GA, Willett WC. Reproductive Risk Factors in a Prospective Study of Breast Cancer: The Nurses’ Health Study. American Journal of Epidemiology; 1994;139(8):819–835.
Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. The Lancet; 2001;358(9291):1389–1399.
Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, et al. BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews. Clinical Cancer Research; 2004;10(9):2918–21. doi; 10.1158/1078-0432.CCR-03-0604
Islam D, Islam MS, Dorin SI, et al. Prevalence of Breast Cancer Subtypes Among Different Ethnicities and Bangladeshi Women: Demographic, Clinicopathological, and Integrated Cancer Informatics Analysis. Cancer Informatics; 2023;17;22. doi:10.1177/11769351221148584
Ye X, Zhang Y, He Y, et al. Association between Consumption of Artificial Sweeteners and Breast Cancer Risk: A Systematic Review and Meta-Analysis of Observational Studies. Nutrition and Cancer; 2023; 16;75(3):795–804. doi: 10.1080/01635581.2023.2178957
Shin S, Fu J, Shin WK, et al. Association of food groups and dietary pattern with breast cancer risk: A systematic review and meta-analysis. Clinical Nutrition; 2023;42(3):282–97. doi: 10.1016/j.clnu.2023.01.003
Fazliddinovna MG. Oncopsychology of patients with breast cancer after treatment. Scholastic: Journal of Natural and Medical Education; 2023;2(2):111–6.
Kayaalp O. Kanser Kemoterapisinin Esasları Ve Antineoplastik İlaçlar. In: Rasyonel Tedavi yönünden Tıbbi Farmakoloji. Ankara: Pelikan Yayıncılık; 2009. p. 323–43.
Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clinical Cancer Research; 1998;4(3):527–34.
Howell SJ, Johnston SRD, Howell A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Practice & Research Clinical Endocrinology & Metabolism; 2004 ;18(1):47–66. doi: 10.1016/j.beem.2003.08.002
Stearns V. Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine. Cancer Spectrum Knowledge Environment; 2003;95(23):1758–1764. doi: 10.1093/jnci/djg108
Desta Z, Ward BA, Soukhova NV, et al. Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6. Journal of Pharmacology and Experimental Therapeutics; 2004;310(3):1062–1075. doi: 10.1124/jpet.104.065607
Schroth W, Winter S, Mürdter T, et al. Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen. Frontiers in Pharmacology; 2017;24;8. doi: 10.3389/fphar.2017.00582
Hussaarts K, Hurkmans D, Oomen-de Hoop E, et al. Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen. Cancers; 2019;11(3):403. doi: 10.3390/cancers11030403
De Oliveira ERS, Penha LRLN, Diniz DM, et al. The Effect of CYP2D6 Inhibitors on The Therapeutic Efficacy of Tamoxifene: Literature Review. Revista Foco; 2024;17(2):e4388. doi: 10.54751/revistafoco.v17n2-041
Lammers LA, Mathijssen RHJ, van Gelder T, et al. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. British Journal of Cancer; 2010;103(6):765–771. doi: 10.1038/sj.bjc.6605800
Binkhorst L, Bannink M, de Bruijn P, et al. Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. Clinical Pharmacokinetics; 2016;55(2):249–255. doi: 10.1007/s40262-015-0315-x
N.V.S. Venugopal, Nizampatnam, S. Tirumala Jagadeesh. Design and Synthesis of Novel Benzoazepinone Derivatives as Potent Estrogen Receptor Alpha Inhibitors. 2023; Preprint. doi: 10.21203/rs.3.rs-3632344/v1
Čmejlová V. Adjuvant hormone therapy in young women with early breast cancer in 2023. Onkologie; 2023;17(3):140–144. doi: 0.36290/xon.2023.028
Ding H, Fang L, Xin W, et al. Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer. European Journal of Cancer Care; 2017;26(6):e12733. doi: 10.1111/ecc.12733
Ellis MJ. Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer. The Breast; 2017;34:104–107.
Nave R, Klein S, Müller A, et al. Absence of Effect of Intravaginal Miconazole, Clindamycin, Nonoxynol‐9, and Tampons on the Pharmacokinetics of an Anastrozole/Levonorgestrel Intravaginal Ring. The Journal of Clinical Pharmacology; 2018;58(1):97–106.
Bonneterre J, Thürlimann B, Robertson JFR, et al. Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. Journal of Clinical Oncology; 2000;18(22):3748–3757.
Gibson L, Lawrence D, Dawson C, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database of Systematic Reviews; 2009. doi: 10.1002/14651858.CD003370.pub3
Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial. Journal of Clinical Oncology; 2000;18(22):3758–3767. doi: 10.1200/JCO.2000.18.22.3758
Vergote I, Bonneterre J, Thürlimann B, et al. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. European Journal of Cancer; 2000;36:84–85.
Cuzick J, Chu K, Keevil B, et al. Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial. The Lancet Oncology; 2024;25(1):108–116 doi: 10.1016/S1470-2045(23)00578-8.
Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG. Inhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proceedings of the National Academy of Sciences; 1990;87(17):6883–6887. doi: 10.1073/pnas.87.17.6883
Nathan MR, Schmid PA. Review of Fulvestrant in Breast Cancer. Oncology and Therapy; 2017;5(1):17–29. doi: 10.1007/s40487-017-0046-2
Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. British Journal of Cancer; 2004;90(Suppl 1):S2–S6. doi: 10.1038/sj.bjc.6601629
Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet; 2016;388(10063):2997–3005. doi: 10.1016/S0140-6736(16)32389-3
Fasching PA, Jerusalem GHM, Pivot X, Martin M, De Laurentiis M, Blackwell KL, et al. Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3. Journal of Clinical Oncology; 2016;34:TPS624. doi: 10.1200/JCO.2016.34.15_suppl.TPS624
Fulvestrant clinical trials. 2024. (16/02/2024 tarihinde https://clinicaltrials.gov/study/NCT05524584 adresinden ulaşılmıştır).
Conn PM, Crowley WF. Gonadotropin-Releasing Hormone and Its Analogues. New England Journal of Medicine; 1991;324(2):93–103 doi: 10.1056/NEJM199101103240205
Klijn JGM, Blamey RW, Boccardo F, et al. Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized Trials. Journal of Clinical Oncology; 2001;19(2):343–353. doi: 10.1200/JCO.2001.19.2.343
Aydiner A, Kilic L, Yildiz I, et al. Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients. Medical Oncology. 2013;30(1):354 doi: 10.1007/s12032-012-0354-1
Boccardo F, Rubagotti A, Amoroso D, et al. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. Cancer Chemotherapy and Pharmacology; 1999;43(6):461–466. doi: 10.1007/s002800050924
Goserelin clinical trials. 2024. (16/02/2024 tarihinde https://classic.clinicaltrials.gov/ct2/show/NCT05720260 adresinden ulaşılmıştır).